T2 Biosystems Inc

NASDAQ:TTOOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

Contact Information

Headquarters

101 Hartwell AveLEXINGTON, MA, United States 02421-3125

Phone

781-457-1200

Fax

781-357-3080

Executives

Chairman of the Board, President, Chief Executive Officer

John Sperzel

Chief Financial Officer

John Sprague

Senior Vice President, General Counsel

Michael Gibbs

Senior Vice President of Science Research and Development

Roger Smith

Chief Commercial Officer

Brett Giffin